Sino Biological Inc. announced a CRO services partnership with Ainnocence Inc. of San Jose, California. Under the terms of this partnership, Sino Biological will add Ainnocence's cutting-edge artificial intelligence-based prediction technology to its current antibody development CRO services offering. The AI-based platform enables fast, efficient, and accurate prediction of antibody-antigen interaction, including binding affinity assessment.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
70.98 CNY | +1.55% | -0.81% | -13.86% |
05-15 | Sino Biological,Inc. Approves Cash Dividend for the Year 2023 | CI |
04-28 | Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.86% | 1.25B | |
+51.13% | 54.63B | |
-4.95% | 39.92B | |
+37.60% | 38.82B | |
+15.49% | 26.86B | |
-12.56% | 26.22B | |
-21.61% | 18.78B | |
+25.32% | 12.21B | |
+1.97% | 12.16B | |
+26.93% | 11.94B |
- Stock Market
- Equities
- 301047 Stock
- News Sino Biological,Inc.
- Sino Biological and Ainnocence Partner to Offer Next-Generation CRO Antibody Development Services